What the COSENTYX TV commercial - Years is about.
COSENTYX is a medication used to treat certain autoimmune diseases such as psoriasis. A recent TV spot for the medication, titled "Years," features music icon Cyndi Lauper.
The commercial begins with Lauper discussing the physical and emotional toll that living with psoriasis can take on a person. She speaks candidly about her own experiences with the disease, including feeling embarrassed and self-conscious about her skin.
The camera then cuts to footage of Lauper performing her hit song "True Colors" in concert. The footage is overlaid with images of people living with psoriasis, highlighting the various locations on the body where the disease can appear.
Throughout the commercial, Lauper's voice is heard singing an a cappella version of the COSENTYX jingle. The lyrics, "I have psoriasis, but I'm not alone, cosentyx, a way to treat, a way to be shown," convey the message that COSENTYX can help people living with psoriasis to lead a better life.
The commercial ends with Lauper encouraging viewers to speak to their doctors about COSENTYX and the benefits it can provide.
The striking commercial is both informative and empowering, offering hope to those living with psoriasis and highlighting the importance of seeking out effective treatments. Cyndi Lauper's powerful message and performance make the TV spot a memorable one.
COSENTYX TV commercial - Years produced for
COSENTYX (Psoriasis)
was first shown on television on October 28, 2019.
Frequently Asked Questions about cosentyx tv spot, 'years' featuring cyndi lauper
Musician Cyndi Lauper was afraid to show her skin and speaks about how painful her psoriasis was. With the help of Cosentyx, she's been clear for over four years and doesn't really think about her skin condition anymore.
COSENTYX TV Spot, 'Enough' Featuring Cyndi Lauper.
The list (or wholesale) price for COSENTYX, as of January 2023 is $6,924.26 a month for either 150-mg or 300-mg dose strength self-injection packages. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less. A month is defined as once every 4 weeks.
Very few studies have directly compared Cosentyx with Humira but one, called the EXCEED trial compared the two biologics in people with psoriatic arthritis. This trial showed that treatment with Cosentyx was similar to that with Humira (or that Cosentyx was not superior to Humira).
The list (or wholesale) price for COSENTYX, as of January 2023 is $6,924.26 a month for either 150-mg or 300-mg dose strength self-injection packages. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less. A month is defined as once every 4 weeks.
87% OF SKYRIZI PATIENTS ACHIEVED PASI 90 AT WEEK 52 VS 57% OF COSENTYX® (secukinumab) PATIENTS (NRI) SOURCING: In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.
Medicare prescription drug plans typically list Cosentyx on Tier 5 of their formulary. Generally, the higher the tier, the more you have to pay for the medication. Most plans have 5 tiers.
Other reasons for a denial of Cosentyx include how the insurer has tiered biologics or the increased number of insurance requirements listed in authorization forms. Of course, the ultimate reason most prescription drugs are denied lies in the cost of the drug.
COSENTYX was proven to inhibit the progression of joint structural damage.
COSENTYX is proven to help stop further joint damage. Based on data from X-rays of the hands and feet at 6 months. For adults taking the 300-mg dose of COSENTYX.
And Cosentyx causes fewer side effects, particularly serious side effects, than Humira. But it's also important to consider your health history. For example, if you have inflammatory bowel disease, taking Cosentyx could make it worse. On the other hand, Humira is approved to treat this condition.
Very few studies have directly compared Cosentyx with Humira but one, called the EXCEED trial compared the two biologics in people with psoriatic arthritis. This trial showed that treatment with Cosentyx was similar to that with Humira (or that Cosentyx was not superior to Humira).